-
-
公开(公告)号：KR1020140120831A
公开(公告)日：2014-10-14
申请号：KR1020140037574
申请日：2014-03-31
Applicant: 삼성전자주식회사
IPC: C07K16/42 , G01N33/53 , A61K39/395 , A61P35/00
CPC classification number: C07K16/4258 , C07K2317/56 , C07K2317/565
Abstract: According to an embodiment of the present invention, provided is an anti-idiotype antibody against anti-c-Met antibody and, more specifically, provided is an anti-idiotype antibody against an anti-c-Met antibody specifically binding to (and/or recognizing) the idiotope region of the anti-c-Met antibody. The anti-idiotype antibody against the anti-c-Met antibody is an antibody to recognize the idiotope of the c-Met antibody as an epitope, specifically targeting the idiotope of the anti-c-Met antibody or specifically binding to the idiotope of the c-Met antibody.
Abstract translation: 根据本发明的一个实施方案，提供了针对抗c-Met抗体的抗独特型抗体，更具体地说，提供了针对特异性结合（和/或）抗-c-Met抗体的抗c-Met抗体的抗独特型抗体 识别）抗c-Met抗体的特异性区域。 针对抗c-Met抗体的抗独特型抗体是将c-Met抗体的特异性识别为表位的抗体，特异性靶向抗c-Met抗体的特异性或特异性结合到抗-c-Met抗体的特异性 c-Met抗体。
-
公开(公告)号：KR1020140035266A
公开(公告)日：2014-03-21
申请号：KR1020130108913
申请日：2013-09-11
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61K47/48 , A61P35/00
CPC classification number: A61K39/3955 , A61K45/06 , C07K16/2863 , C07K2317/24
Abstract: Provided is a pharmaceutical composition for a combination therapy which contains an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof as an active ingredient for preventing and/or treating c-Met and angiogenic factor induced diseases. The pharmaceutical composition for the combination therapy has a superior synergistic effect, thereby more effective treatments are available.
Abstract translation: 提供了含有血管生成抑制剂和抗c-Met抗体或其抗原结合片段作为预防和/或治疗c-Met和血管生成因子诱导的疾病的活性成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，从而可获得更有效的治疗。
-
-
-
Patent Agency Ranking
公开(公告)号：KR1020130037189A
公开(公告)日：2013-04-15
申请号：KR1020120110584
申请日：2012-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
Abstract: PURPOSE: An anti-c-Met antibody and a pharmaceutical composition containing the same are provided to effectively prevent or treat cancer. CONSTITUTION: An anti-c-Met antibody comprises the followings: a heavy chain variable region containing one or more heavy chain complementarily determining regions selected from CDR-H1 with an amino acid sequence of sequence number 4, CDR-H2 with an amino acid sequence of sequence number 5, and CDR-H3 with an amino acid sequence of sequence number 6; and a heavy chain variable region containing one or more heavy chain complementarily determining regions selected from the group consisting of CDR-L1 with an amino acid sequence of sequence number 7, CDR-L2 with an amino acid sequence of sequence number 8, and CDR-L3 with an amino acid sequence of sequence number 9.
Abstract translation: 目的：提供抗c-Met抗体及含有该抗体的药物组合物以有效预防或治疗癌症。 构成：抗c-Met抗体包含以下重链可变区：含有一个或多个选自具有序列号4的氨基酸序列的CDR-H1的重链互补决定区的重链可变区，具有氨基酸序列的CDR-H2 序列号5的CDR-H3和具有序列号6的氨基酸序列的CDR-H3; 和含有一个或多个重链互补决定区的重链可变区，所述重链互补决定区选自CDR-L1与序列号7的氨基酸序列，CDR-L2与序列号8的氨基酸序列，CDR- L3具有序列号9的氨基酸序列。
-
公开(公告)号：KR1020140119317A
公开(公告)日：2014-10-10
申请号：KR1020130033872
申请日：2013-03-28
Applicant: 삼성전자주식회사
IPC: C07K16/46 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2863 , A61K2039/505 , C07K14/71 , C07K2317/10 , C07K2317/24 , C07K2317/515 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/00
Abstract: Provided are a fusion protein with anti-c-Met antibodies and VEGF binding fragments; double target antibodies including the fusion protein; polynucleotide which encodes the fusion protein; transformants including the polynucleotide; a pharmaceutical composition including the double target antibodies as an active ingredient; and a method for manufacturing the double target antibodies which target both c-Met and VEGF with improved anticancer and inhibitory effect of new blood vessel, wherein the method comprises a step of connecting anti-c-Met antibodies with VEGF binding fragments.
Abstract translation: 提供了具有抗c-Met抗体和VEGF结合片段的融合蛋白; 双重靶抗体，包括融合蛋白; 编码融合蛋白的多核苷酸; 包括多核苷酸的转化体; 包含双重靶抗体作为活性成分的药物组合物; 以及制备靶向c-Met和VEGF的双重靶抗体的方法，其具有改善的新血管的抗癌和抑制作用，其中该方法包括将抗c-Met抗体与VEGF结合片段连接的步骤。
-
公开(公告)号：KR1020130036993A
公开(公告)日：2013-04-15
申请号：KR1020110101292
申请日：2011-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/92
Abstract: PURPOSE: An antibody which is specifically bonded to epitope within SEMA domain of c-Met is provided to efficiently prevent or treat cancer. CONSTITUTION: An antibody which is specifically bonded to epitope within SEMA domain of c-Met is indicated as amino acid sequence of sequence number 1. An epitope is a polypeptide having amino acid sequence of sequence number 2 or sequence number 3.
Abstract translation: 目的：提供与c-Met的SEMA结构域内的表位特异性结合的抗体，以有效预防或治疗癌症。 构成：与c-Met的SEMA结构域内的表位特异性结合的抗体表示为序列号1的氨基酸序列。表位是具有序列号2或序列号3的氨基酸序列的多肽。
-
-
公开(公告)号：KR1020150082121A
公开(公告)日：2015-07-15
申请号：KR1020150000956
申请日：2015-01-06
Applicant: 삼성전자주식회사
CPC classification number: G01N33/6863 , C12Q1/6874 , C12Q2600/106 , G01N33/5008
Abstract: c-Met 저해제의효능예측및/또는효능검증을위한바이오마커, 상기바이오마커의검출물질을포함하는 c-Met 저해제의효능예측및/또는검정용조성물, 상기바이오마커의검출물질을포함하는 c-Met 저해제의적용대상선별용조성물, 상기바이오마커를이용하는 c-Met 저해제의효능예측및/또는효능검증방법, 상기바이오마커를이용하는 c-Met 저해제의적용대상선별방법, 및상기선별된적용대상에 c-Met 저해제를투여하는단계를포함하는암의예방및/또는치료방법이제공된다.
Abstract translation: 本发明提供：用于预测和/或验证c-Met抑制剂的作用的生物标志物; 用于预测和/或验证包括用于检测生物标志物的物质的c-Met抑制剂的作用的组合物; 用于鉴定包含用于检测生物标志物的物质的c-Met抑制剂的物质的组合物; 用于使用该生物标志物预测和/或验证c-Met抑制剂的作用的方法; 使用生物标志物选择使用c-Met抑制剂的对象的方法; 以及用于预防和/或治疗癌症的方法，其包括将c-Met抑制剂施加到所选择的对象的步骤。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.025 seconds)
